A scientist using a pipette.

50 Years of Bold Research for a Better Tomorrow

BrightFocus Foundation is a premier private funder of research to defeat Alzheimer’s, macular degeneration, and glaucoma. We've invested nearly $300 million in research grants to more than 6,000 scientists worldwide, catalyzing countless scientific breakthroughs, life-enhancing treatments, and diagnostic tools.

Recently Funded

Learn more about grants awarded in the most current fiscal year (nearly $25 million in funding for 95new awards in FY2022).

Culture of cortical neurons.

Nearly $14 million in funding for 55 new ADR awards in FY22.

A senior man having an eye exam.

Nearly $7 million in funding for 21 new MDR awards in FY22.

A close up of an eye.

Nearly $4 million in funding for 19 new NGR awards in FY22.

Latest News

Research News

A team including two BrightFocus-funded Alzheimer’s disease researchers discovered that deteriorating neurons are a source of human brain inflammation, which could pave the way for therapeutics to prevent or treat Alzheimer’s disease.

Dec 20, 2022
Research News

A new blood test that could facilitate a more accurate diagnosis of Alzheimer’s during the initial phases of the disease is on the way—rooted in critical early support from Alzheimer’s Disease Research, a program of BrightFocus Foundation. Catching the disease as soon as possible offers affected individuals the greatest gift of all—more time to spend with loved ones and explore disease management and treatment options.

Dec 06, 2022
Research News

Clinical trial results released Nov. 29 for lecanemab, a drug targeting early Alzheimer’s disease, reported a moderate slowing of cognitive decline in patients by 25% through the removal of amyloid-beta (Aβ) in the brain.

Nov 30, 2022
Research News

A new oral pill for geographic atrophy is being tested in an early-stage clinical trial.

Aug 12, 2022